加速康复路径下微创结直肠肿瘤手术延长静脉血栓栓塞预防的作用
该回顾性队列研究纳入2016至2024年加拿大高容量学术中心1043例择期微创结直肠肿瘤切除患者,比较出院后延长达肝素预防与未延长预防的差异。结果显示术后30天症状性VTE总发生率为0.5%,未延长预防组VTE发生率显著高于延长预防组(1.4% vs 0.1%,p=0.010),但绝对风险降低幅度小,出血并发症无显著差异。
要点
- 成熟ERAS路径下微创结直肠肿瘤切除后症状性VTE发生率很低(0.5%)。
- 延长预防与VTE显著降低相关(1.4% vs 0.1%,p=0.010),但绝对风险降低小。
- 两组总体出血及临床显著出血无显著差异。
核心结论
- 在成熟ERAS路径下微创结直肠切除患者中,出院后症状性VTE发生率很低。
- 延长血栓预防与VTE事件统计学显著降低相关,但绝对风险降低幅度小。
研究设计与样本
- 回顾性队列研究,纳入2016年1月至2024年12月加拿大高容量学术中心所有因肿瘤行择期微创结直肠切除的成年患者。
- 排除开腹手术、急诊手术或接受治疗性抗凝的患者;最终主要分析纳入1043例(未延长预防351例,延长预防692例)。
- 所有患者接受标准院内血栓预防;2018年3月前延长预防由医生酌情决定,之后纳入ERAS方案。
主要发现
- 术后30天出院后VTE总发生率为0.5%(6/1043)。
- 未延长预防组VTE发生率高于延长预防组:5/351(1.4%)vs 1/692(0.1%),p=0.010。
- 两组总体出血或临床显著出血无显著差异。
关键数值与推荐
- 延长预防方案为出院后达肝素5000 U使用28天。
- 主要结局为术后30天内症状性出院后VTE。
- 次要结局包括出血并发症、住院时间、急诊就诊和再入院。
临床怎么用
- 在成熟ERAS路径下,微创结直肠肿瘤切除后出院后症状性VTE风险很低,可据此评估延长预防的必要性。
- 延长达肝素预防虽降低VTE事件,但绝对获益小,需结合个体风险与出血风险权衡。
局限性
- 回顾性设计,延长预防非随机分配,存在选择偏倚可能。
- 2018年3月前延长预防由医生酌情决定,之后纳入ERAS方案,存在时间趋势影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with colorectal cancer are at increased risk of venous thromboembolism (VTE) due to malignancy-associated hypercoagulability and the physiologic stress of surgery. Current guidelines recommend extended-duration thromboprophylaxis for up to 28 days following major abdominal or pelvic cancer surgery. However, its effectiveness in patients managed by Enhanced Recovery After Surgery (ERAS) pathways is uncertain. This study evaluated the effectiveness of extended thromboprophylaxis after minimally invasive colorectal resection managed within a mature ERAS program in reducing clinically significant VTE. METHODS: A retrospective cohort study was conducted including all adult patients undergoing elective minimally invasive colorectal resection for neoplasia at a high-volume Canadian academic centre between 01/2016 and 12/2024. Patients undergoing open surgery, emergency procedures, or receiving therapeutic anticoagulation were excluded. All patients received standard in-hospital thromboprophylaxis. Extended thromboprophylaxis with dalteparin 5000 U for 28 days post-discharge was provided at the physician's discretion before 03/2018 and was subsequently included in the ERAS protocol. The primary outcome was symptomatic post-discharge VTE within 30 days of surgery. Secondary outcomes included bleeding complications, length of stay, emergency department visits, and readmissions. RESULTS: A total of 1043 included in the primary analysis after excluding inpatient VTE events (n=351 patients did not receive extended prophylaxis, n=692 received extended prophylaxis). The incidence of post-discharge VTE was 0.5% (6/1043). There was a higher incidence of VTEs in the -eDVTp group compared to the +eDVTp group [5/351(1.4%) vs. 1/692 (0.1%), p=0.010]. Post-discharge VTE was significantly higher in patients who did not receive extended prophylaxis compared with those who did (1.4% vs. 0.1%, p = 0.010). There were no significant differences in overall or clinically significant bleeding between groups. CONCLUSIONS: In patients undergoing minimally invasive colorectal resection within a mature ERAS pathway, the incidence of symptomatic post-discharge VTE is very low. Although extended thromboprophylaxis was associated with a statistically significant reduction in VTE events, the absolute risk reduction was small.
引用
- AlMarzooqi N, Robert L, Feldman LS, et al. Role of extended venous thromboembolism prophylaxis in patients with colorectal neoplasia who underwent minimally invasive colorectal surgery within an enhanced recovery after surgery protocol. Surg Endosc. 2026. PMID: 42844369. doi:10.1007/s00464-026-13445-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。